KSD-201
Phase 1Biologic
KSD-201 is one of 48 biologic programs targeting Renal Cell Carcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
86 competitors in Renal Cell Carcinoma
#DrugCompanyPhaseTrials
1Sutent
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Lenvima
EisaiPhase 3
Inlyta
PPrism Pharmaceuticals
Phase 3
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Fotivda
AAVEO Pharmaceuticals, Inc.
Phase 3
Zanzalintinib
Merck & Co.Phase 3
Libtayo
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KSD-201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- KKousai Bio Co., Ltd.